Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015

  • ID: 3099704
  • Report
  • 226 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Alcon, Inc.
  • Bayer AG
  • EyeCyte, Inc.
  • iCo Therapeutics Inc.
  • Mesoblast Limited
  • Oxford BioMedica plc
  • MORE
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015

Summary

This, ‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alcon, Inc.
  • Bayer AG
  • EyeCyte, Inc.
  • iCo Therapeutics Inc.
  • Mesoblast Limited
  • Oxford BioMedica plc
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Wet (Neovascular / Exudative) Macular Degeneration Overview
Therapeutics Development
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration – Overview
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration – Comparative Analysis
Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics under Development by Companies
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Wet (Neovascular / Exudative) Macular Degeneration – Products under Development by Companies
Wet (Neovascular / Exudative) Macular Degeneration – Companies Involved in Therapeutics Development
Alcon, Inc.
Allergan, Inc.
AlphaMab Co., Ltd
Amakem NV
Avalanche Biotechnologies, Inc.
Bayer AG
BIOCAD
Boehringer Ingelheim GmbH
Charlesson LLC.
Circadian Technologies Limited
Clearside BioMedical, Inc.
EyeCyte, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
GlaxoSmithKline plc
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Iconic Therapeutics, Inc.
Intas Pharmaceuticals Ltd.
Kala Pharmaceuticals, Inc.
Lpath, Inc.
Mesoblast Limited
Neurotech Pharmaceuticals, Inc.
Novartis AG
Ohr Pharmaceutical Inc.
Ophthotech Corp.
Oxford BioMedica plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
pSivida Corp.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Resolvyx Pharmaceuticals, Inc
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Tacere Therapeutics, Inc.
ThromboGenics NV
TRACON Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc.
DWet (Neovascular / Exudative) Macular Degeneration – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abicipar pegol - Drug Profile
AC-301 - Drug Profile
aflibercept (recombinant) - Drug Profile
AGN-151200 - Drug Profile
ALG-1001 - Drug Profile
AMA-0428 - Drug Profile
ARC-1905 - Drug Profile
AVA-101 - Drug Profile
AVA-201 - Drug Profile
bertilimumab - Drug Profile
bevacizumab biosimilar - Drug Profile
BI-144807 - Drug Profile
BI-30089 - Drug Profile
C16Y Peptide - Drug Profile
CLT-005 - Drug Profile
conbercept - Drug Profile
DE-120 - Drug Profile
doxorubicin pegylated nanoparticle - Drug Profile
EC-200 - Drug Profile
EC-400 - Drug Profile
ENV-705 - Drug Profile
fluocinolone acetonide - Drug Profile
GB-101 - Drug Profile
Gene Therapy for Wet Age-Related Macular Degeneration - Drug Profile
GZ-402663 - Drug Profile
hI-con1 - Drug Profile
HMR-59 - Drug Profile
LFG-316 - Drug Profile
Lpathomab - Drug Profile
LT-1009 - Drug Profile
MPC-MICRO-IO - Drug Profile
NM-9405 - Drug Profile
NT-503 - Drug Profile
NT-506 - Drug Profile
ocriplasmin (recombinant) - Drug Profile
OPT-302 - Drug Profile
PAN-90806 - Drug Profile
pazopanib hydrochloride - Drug Profile
pegpleranib sodium - Drug Profile
PF-05206388 - Drug Profile
PF-655 - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
REGN-21763 - Drug Profile
regorafenib - Drug Profile
RetinoStat - Drug Profile
RG-7716 - Drug Profile
RTH-258 - Drug Profile
RX-20001 - Drug Profile
SK-1011 - Drug Profile
Small Molecule to Inhibit Receptor Tyrosine Kinase for Wet Age-Related Macular Degeneration - Drug Profile
Small Molecules for Age Related Macular Degeneration - Drug Profile
Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile
Small Molecules to Inhibit VEGF for Wet AMD - Drug Profile
squalamine lactate - Drug Profile
TRC-105 - Drug Profile
triamcinolone acetonide - Drug Profile
TT-211 - Drug Profile
TT-231 - Drug Profile
X-82 - Drug Profile
XV-615 - Drug Profile
Wet (Neovascular / Exudative) Macular Degeneration – Recent Pipeline Updates
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects
Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products
Wet (Neovascular / Exudative) Macular Degeneration – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2015
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Alcon, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Allergan, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by AlphaMab Co., Ltd, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Amakem NV, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Avalanche Biotechnologies, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Bayer AG, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by BIOCAD, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Charlesson LLC., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Circadian Technologies Limited, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clearside BioMedical, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by EyeCyte, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Genzyme Corporation, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by GlaxoSmithKline plc, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by iCo Therapeutics Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Iconic Therapeutics, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Intas Pharmaceuticals Ltd., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Kala Pharmaceuticals, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Lpath, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Mesoblast Limited, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Novartis AG, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ophthotech Corp., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Oxford BioMedica plc, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by PanOptica, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfenex Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfizer Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by pSivida Corp., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Quark Pharmaceuticals, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by ReGenX Biosciences, LLC, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Tacere Therapeutics, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by ThromboGenics NV, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TRACON Pharmaceuticals, Inc., H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TWi Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics – Recent Pipeline Updates, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects, H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..1), H1 2015
Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2015
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Alcon, Inc.
Allergan, Inc.
AlphaMab Co., Ltd
Amakem NV
Avalanche Biotechnologies, Inc.
Bayer AG
BIOCAD
Boehringer Ingelheim GmbH
Charlesson LLC.
Circadian Technologies Limited
Clearside BioMedical, Inc.
EyeCyte, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
GlaxoSmithKline plc
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Iconic Therapeutics, Inc.
Intas Pharmaceuticals Ltd.
Kala Pharmaceuticals, Inc.
Lpath, Inc.
Mesoblast Limited
Neurotech Pharmaceuticals, Inc.
Novartis AG
Ohr Pharmaceutical Inc.
Ophthotech Corp.
Oxford BioMedica plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
pSivida Corp.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Resolvyx Pharmaceuticals, Inc
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Tacere Therapeutics, Inc.
ThromboGenics NV
TRACON Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll